{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:57:16Z","timestamp":1794556636344,"version":"4.9.1"},"reference-count":78,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,10,3]],"date-time":"2006-10-03T00:00:00Z","timestamp":1159833600000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hemodialysis International"],"published-print":{"date-parts":[[2006,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The dialysate calcium (Ca) concentration for hemodialysis (HD) patients can be adjusted to manage more optimally the body's Ca and phosphate balance, and thus improve bone metabolism as well as reduce accelerated arteriosclerosis and cardiovascular mortality. The appropriate dialysate Ca concentration allowing this balance should be prescribed to each individual patient depending on a multitude of variable factors relating to Ca load. A lower dialysate Ca concentration of 1.25 to 1.3\u2003mmol\/L will permit the use of vitamin D supplements and Ca\u2010based phosphate binders in clinical practice, with much less risk of Ca loading and resultant hypercalcemia and calcification. Low Ca baths are useful in the setting of adynamic bone disease where an increase in bone turnover is required. However, low Ca levels in the dialysate may also predispose to cardiac arrhythmias and hemodynamically unstable dialysis sessions with intradialytic hypotension. Higher Ca dialysate is useful to sustain normal serum Ca levels where patients are not taking Ca\u2010based binders or if Ca supplements are not able to normalize serum levels. Suppression of hyperparathyroidism is also effective with dialysate Ca of 1.75\u2003mmol\/L, but hypercalcemia, metastatic calcification, and oversuppression of parathyroid hormone are risks. Dialysate Ca of 1.5\u2003mmol\/L may be a compromise between bone protection and reduction in cardiovascular risk for conventional HD and is a common concentration used throughout the world. The increase in longer, more frequent dialysis such as short\u2010daily and nocturnal HD, however, provides another challenge with regard to optimal dialysate Ca levels and higher levels of 1.75\u2003mmol\/L are probably indicated in this setting. Difficulties in determining the ideal dialysate Ca occur because of the complex pathophysiology of bone and mineral metabolism in HD patients and there needs to be a balance between dialysis prescription and other treatment modalities. To optimize management of the abnormal Ca balance, other aspects of this disorder need to be more fully clarified and, with evolving medications for phosphate control and treatment of secondary hyperparathyroidism, as well as the emergence of a multitude of different HD regimes, further studies are required to make definitive recommendations. At present, we need to maintain flexibility with HD treatments and so dialysate Ca needs to be individualized to meet the specific requirements of patients by optimizing management of renal bone disease and simultaneously reducing metastatic calcification and cardiovascular disease.<\/jats:p>","DOI":"10.1111\/j.1542-4758.2006.00125.x","type":"journal-article","created":{"date-parts":[[2006,10,3]],"date-time":"2006-10-03T04:40:27Z","timestamp":1159850427000},"page":"326-337","source":"Crossref","is-referenced-by-count":56,"title":["Review of dialysate calcium concentration in hemodialysis"],"prefix":"10.1111","volume":"10","author":[{"given":"Nigel","family":"TOUSSAINT","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"COONEY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"KERR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,10,3]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-139x.2001.00013.x"},{"issue":"3","key":"e_1_2_5_3_2","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation.","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(74)90811-0"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198607173150304"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1989.277"},{"key":"e_1_2_5_7_2","first-page":"105","article-title":"High\u2010dose calcium carbonate with stepwise reduction in dialysate calcium concentration","volume":"4","author":"Sawyer N","year":"1989","journal-title":"Effective phosphate control and aluminium avoidance in hemodialysis patients"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/5.10.874"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.1998.v32.pm9808139"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1998.00875.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.09502.x"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(88)80099-4"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1993.92"},{"key":"e_1_2_5_14_2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1681\/ASN.V61132","article-title":"Low\u2010calcium dialysate stimulates parathormone secretion and its long\u2010term use worsens secondary hyperparathyroidism","volume":"6","author":"Fernandez E","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_5_15_2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1681\/ASN.V74635b","article-title":"Low\u2010calcium dialysate worsens secondary hyperparathyroidism","volume":"7","author":"Argiles A","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-139X.1988.tb00708.x"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00434.x"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-005-0350-2"},{"issue":"7","key":"e_1_2_5_19_2","first-page":"37","article-title":"The choice of the dialysate calcium concentration in the management of patients on hemodialysis and haemofiltration","volume":"18","author":"Malberti F","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_5_20_2","first-page":"1179","article-title":"Predictors and consequences of altered mineral metabolism","volume":"67","author":"Young E","year":"2005","journal-title":"The dialysis outcomes and practice patterns study"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.5.723"},{"key":"e_1_2_5_22_2","first-page":"47A","article-title":"Sevelamer vs calcium\u2010containing phosphate binders and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"16","author":"Young E","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-139X.1990.tb00001.x"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/13.suppl_3.62"},{"key":"e_1_2_5_25_2","first-page":"75","article-title":"Dialysate calcium concentration decrease exacerbates secondary hyperparathyroidism in dialysis patients given calcium carbonate as a phosphate binder","volume":"2","author":"Malberti F","year":"1991","journal-title":"J Nephrol"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1159\/000188934"},{"key":"e_1_2_5_27_2","first-page":"27","article-title":"Use of the equipment for hemodialysis in the diagnosis of calcium metabolism disorders in terminal chronic renal failure","volume":"1","author":"Ermakova I","year":"1991","journal-title":"Med Tekh"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1594.2004.47207.x"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-104-3-358"},{"key":"e_1_2_5_30_2","first-page":"190","article-title":"Influence of changes in ionized calcium on cardiovascular reactivity during hemodialysis","volume":"47","author":"Van Kuijk W","year":"1997","journal-title":"Clin Nephrol"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.1998.v32.pm9669433"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh102"},{"key":"e_1_2_5_33_2","volume-title":"US Renal Data System USRDS 1999 Annual Report","author":"The National Institute of Diabetes and Digestive and Kidney Diseases.","year":"1999"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.1998.v32.pm9820470"},{"key":"e_1_2_5_35_2","first-page":"607","article-title":"Association of serum phosphorus and calcium \u00d7 phosphate product with mortality risk in chronic hemodialysis patients","volume":"31","author":"Block G","year":"1998","journal-title":"A national study"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000145894.57533.C4"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000141775.67189.98"},{"key":"e_1_2_5_38_2","first-page":"1315","article-title":"Vascular calcification","volume":"66","author":"Goldsmith D","year":"2006","journal-title":"A stiff challenge for the nephrologist"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1159\/000083713"},{"key":"e_1_2_5_40_2","first-page":"18","article-title":"Vascular calcifications as a footprint of increased calcium load and chronic inflammation in uremic patients","volume":"25","author":"Tetta C","year":"2002","journal-title":"A need for a neutral calcium balance during hemodialysis?"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00581.x"},{"key":"e_1_2_5_42_2","first-page":"2571","article-title":"Electron\u2010beam tomography coronary artery calcium and cardiac events","volume":"107","author":"Kondos G","year":"2003","journal-title":"A 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(96)90363-7"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422003"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-003-0260-0"},{"key":"e_1_2_5_46_2","first-page":"1731","article-title":"Arterial media calcification in end\u2010stage renal disease","volume":"18","author":"London G","year":"2003","journal-title":"Impact on all-cause and cardiovascular mortality"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1161\/hy1001.096358"},{"key":"e_1_2_5_48_2","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2004.19.1.27"},{"key":"e_1_2_5_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1980.93"},{"key":"e_1_2_5_50_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2000.00062.x"},{"key":"e_1_2_5_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(86)80033-6"},{"key":"e_1_2_5_52_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198401053100105"},{"key":"e_1_2_5_53_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-108-4-524"},{"key":"e_1_2_5_54_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00875.x"},{"key":"e_1_2_5_55_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.13.3.213"},{"key":"e_1_2_5_56_2","doi-asserted-by":"publisher","DOI":"10.1159\/000081694"},{"issue":"1","key":"e_1_2_5_57_2","first-page":"1","article-title":"The importance of bone health in end\u2010stage renal disease","volume":"19","author":"Malluche H","year":"2004","journal-title":"Out of the frying pan, into the fire?"},{"key":"e_1_2_5_58_2","doi-asserted-by":"publisher","DOI":"10.1159\/000075565"},{"key":"e_1_2_5_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2005.02.008"},{"key":"e_1_2_5_60_2","first-page":"276","article-title":"Dialysate calcium profiling during hemodialysis","volume":"61","author":"Kyriazis J","year":"2002","journal-title":"Use and clinical implications"},{"key":"e_1_2_5_61_2","first-page":"2835","article-title":"Nocturnal home hemodialysis","volume":"14","author":"Pierratos A.","year":"1999","journal-title":"An update on a 5-year experience"},{"key":"e_1_2_5_62_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000083044.42480.C1"},{"key":"e_1_2_5_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(03)00534-1"},{"key":"e_1_2_5_64_2","first-page":"262A","article-title":"Improvements in phosphate control with short daily in\u2010center hemodialysis (SDHD)","volume":"12","author":"Chan C","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_5_65_2","doi-asserted-by":"publisher","DOI":"10.1590\/S1516-31802001000300004"},{"key":"e_1_2_5_66_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1542-4758.2006.00109.x"},{"key":"e_1_2_5_67_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00228.x"},{"key":"e_1_2_5_68_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1492-7535.2003.01223.x"},{"key":"e_1_2_5_69_2","first-page":"582","article-title":"Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients","volume":"18","author":"Sadek T","year":"2003","journal-title":"An open-label, randomized study"},{"key":"e_1_2_5_70_2","article-title":"The DCOR Trial\u2014A prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients","volume":"16","author":"Suki W","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_5_71_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00247.x"},{"key":"e_1_2_5_72_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1774-9987.2005.00210.x"},{"key":"e_1_2_5_73_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1774-9987.2005.00216.x"},{"key":"e_1_2_5_74_2","first-page":"372","article-title":"Lanthanum carbonate","volume":"2","author":"Locatelli F","year":"2000","journal-title":"Curr Opinion Cardiov Pulm Renal Invest Drugs"},{"key":"e_1_2_5_75_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/15.4.460"},{"key":"e_1_2_5_76_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022536"},{"issue":"90","key":"e_1_2_5_77_2","first-page":"S46","article-title":"The impact of calcimimetic agents on the use of different classes of phosphate binders","author":"Szczech L.","year":"2004","journal-title":"Results of recent clinical trials"},{"key":"e_1_2_5_78_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.310_1.x"},{"key":"e_1_2_5_79_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/15.suppl_5.34"}],"container-title":["Hemodialysis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1542-4758.2006.00125.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1542-4758.2006.00125.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T06:24:54Z","timestamp":1697351094000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1542-4758.2006.00125.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["10.1111\/j.1542-4758.2006.00125.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1542-4758.2006.00125.x","archive":["Portico"],"relation":{},"ISSN":["1492-7535","1542-4758"],"issn-type":[{"value":"1492-7535","type":"print"},{"value":"1542-4758","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}